Sep 19, 2022 8:00am EDT Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update
Sep 15, 2022 5:05pm EDT Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors
Aug 08, 2022 5:00pm EDT Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022
Jun 22, 2022 5:50pm EDT Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)
